Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Urogenital Neoplasms: early-phase trial registry
6 of 12 indexed Urogenital Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 6 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Urogenital Neoplasms: 12 US clinical trials tracked, 6 recruiting.
Urogenital Neoplasms is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition urogenital-neoplasms
OPEN 6 | RECR 50% | LATE 2 | EARLY 7 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Urogenital Neoplasms lists 6 open slots (50% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Urogenital Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Urogenital Neoplasms is recruiting above its size-band peers.
6 of 12 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Urogenital Neoplasms research.
National Cancer Institute (NCI) accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Urogenital Neoplasms enrolment sits around 130 participants.
Median target enrolment is 130 among the 12 trials that report a genuine target (sentinel values excluded). 4 of those (33.3%) plan for fewer than 100 participants.
-
Urogenital Neoplasms research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
National Cancer Institute (NCI)
NCT04923178
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Marengo Therapeutics
NCT05592626
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Pathos AI
NCT06785636
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Cancer Institute (NCI)
NCT04235777
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics
NCT05413850
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
NCT06706921
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company
NCT05288166
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Promontory Therapeutics
NCT02266745
Health Gatherings - For Your Health After Cancer
University of Miami
NCT03344757
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients
University of Michigan
NCT02444195
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
Pharmacyclics
NCT00134186
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology
NCT03081858
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Urogenital Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Urogenital Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Urogenital Neoplasms page
12 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Urogenital Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Urogenital Neoplasms trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urogenital Neoplasms condition card totals 12 registered trials; most-linked intervention TSD-001; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.